The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.La présente invention concerne des conjugués d'oligonucléotides (oligomères) antisens LNA qui ciblent ApoB.